Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx

This page shows the latest Ardelyx news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints. California biotech Ardelyx has a second positive trial for its lead drug tenapanor in chronic kidney disease (CKD), as it waits for an FDA ... Shares in Ardelyx rocketed 72% on the back of the new study on

Latest news

  • Ardelyx buys back drug from AZ to 'accelerate development' Ardelyx buys back drug from AZ to 'accelerate development'

    Now, Ardelyx is paying $25m back to AZ in order to reclaim rights to the programme and "accelerate the clinical development path" for drug. ... Ardelyx still has a $200m partnership in place with Sanofi for NaP2b inhibitors used in the treatment of

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    201. Ardelyx (formerly Nteryx) / Sanofi. Licence. 1. NaP2b inhibitor programme for ESRD.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In keeping with the trend seen with many other biotech deals, Ardelyx has an option to co-promote the product in the US. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics